Long-Term Data Reinforces Tremfya as the Only IL-23 Inhibitor Proven to Substantially Inhibit Structural Joint Damage in Active Psoriatic Arthritis
November 18, 2025
November 18, 2025
RARITAN, New Jersey, Nov. 18 -- Johnson and Johnson Innovative Medicine issued the following news release:
* * *
Long-term data reinforces TREMFYA(R) (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
First-line treatment with TREMFYA(R) shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-estab . . .
* * *
Long-term data reinforces TREMFYA(R) (guselkumab) as the only IL-23 inhibitor proven to substantially inhibit structural joint damage in active psoriatic arthritis
First-line treatment with TREMFYA(R) shows significant inhibition of radiographic progression at Week 24, which was sustained through Week 48, preserving joint health with a well-estab . . .